eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank

4/2018
vol. 43
 
Share:
Share:
more
 
 
abstract:
Clinical immunology

Clinical utility of TSH receptor antibody levels in Graves’ orbitopathy: a comparison of two TSH receptor antibody immunoassays

Gabriela A. Bluszcz, Tomasz Bednarczuk, Zbigniew Bartoszewicz, Agnieszka Kondracka, Klaudia Walczak, Zuzanna Żurecka, Urszula Demkow, Piotr Miśkiewicz

(Centr Eur J Immunol 2018; 43 (4): 405-412)
Online publish date: 2018/12/31
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Introduction
Thyroid stimulating hormone (TSH) receptor antibodies (TRAB) play a role in the development of Graves’ orbitopathy (GO), and measurements of the TRAB level may be helpful in monitoring GO treatment.

Aim of the study
To assess the correlation of TRAB levels measured with two different assays: third-generation TRAB assay (TRAB Cobas) and novel Immulite assay (TRAB Immulite), in patients with moderate-to-severe GO treated with intravenous glucocorticoid pulse therapy (ivGCs).

Material and methods
Forty patients with active, moderate-to-severe GO underwent clinical and laboratory evaluation before, in the middle, and after ivGCs therapy. The correlation of TRAB levels with GO signs was evaluated. Laboratory and clinical findings were compared according to the response to ivGCs. TRAB concentration was measured with Immulite TSI assay and with Elecsys IMA.

Results
All patients were TRAB positive in both assays at the beginning of the treatment. The decrease of both TRAB Immulite and Cobas levels in serum during ivGCs was statistically significant. We observed strong correlation between both TRAB levels before and after ivGCs. There was no statistically significant difference in antibody levels between patients with good response and no response to the treatment. We did not find any correlation between antibody levels and GO features before the therapy, but measurements during ivGCs showed comparable correlation of both TRAB levels with GO activity.

Conclusions
We found similarity between Immulite assay and third-generation TRAB assay in the assessment of patients with GO treated with ivGCs. Both TRAB levels showed comparable correlation with GO activity during ivGCs therapy.

keywords:

Graves’ disease, Graves’ orbitopathy, intravenous glucocorticoids, TSH receptor antibodies, automated immunoassay

references:
Bartalena L, Fatourechi V (2014): Extrathyroidal manifestations of Graves’ disease: a 2014 update. J Endocrinol Invest 37: 691.
Bartalena L, Baldeschi L, Boboridis K, et al. (2016): The 2016 European Thyroid Association/European Group on Graves’ Orbitopathy Guidelines for the Management of Graves’ Orbitopathy. Eur Thyroid J 5: 9-26.
Tanda ML, Piantanida E, Liparulo L, et al. (2013): Prevalence and natural history of Graves’ orbitopathy in a large series of patients with newly diagnosed graves’ hyperthyroidism seen at a single center. J Clin Endocrinol Metab 98: 1443-1449.
Bartalena L, Krassas GE, Wiersinga W, et al. (2012): Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves’ orbitopathy. J Clin Endocrinol Metab 97: 4454-4463.
Estcourt S, Hickey J, Perros P, et al. (2009): The patient experience of services for thyroid eye disease in the United Kingdom: results of a nationwide survey. Eur J Endocrinol 161: 483-487.
Gerding MN, van der Meer JW, Broenink M, et al. (2000): Association of thyrotrophin receptor antibodies with the clinical features of Graves’ ophthalmopathy. Clin Endocrinol (Oxf) 52: 267-271.
Eckstein AK, Plicht M, Lax H, et al. (2006): Thyrotropin receptor autoantibodies are independent risk factors for Graves’ ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab 91: 3464-3470.
Eckstein AK, Plicht M, Lax H, et al. (2004): Clinical results of anti-inflammatory therapy in Graves’ ophthalmopathy and association with thyroidal autoantibodies. Clin Endocrinol (Oxf) 61: 612-618.
Kahaly GJ (2015): Bioassays for TSH receptor antibodies: quo vadis? Eur Thyroid J 4: 3-5.
Zophel K, Roggenbuck D, Wunderlich G, et al. (2010): Continuously increasing sensitivity over three generations of TSH receptor autoantibody assays. Horm Metab Res 42: 900-902.
Smith BR, Hall R (1974): The thyroid stimulating hormone receptor and thyroid stimulating antibodies. J Endocrinol 63: 59-60.
Costagliola S, Morgenthaler NG, Hoermann R, et al. (1999): Second generation assay for thyrotropin receptor antibodies has superior diagnostic sensitivity for Graves’ disease. J Clin Endocrinol Metab 84: 90-97.
Smith BR, Bolton J, Young S, et al. (2004): A new assay for thyrotropin receptor autoantibodies. Thyroid 14: 830-835.
Barbesino G, Tomer Y (2013): Clinical utility of TSH receptor antibodies. J Clin Endocrinol Metab 98: 2247-2255.
Tozzoli R, D’Aurizio F, Villalta D, Giovanella L (2017): Evaluation of the first fully automated immunoassay method for the measurement of stimulating TSH receptor autoantibodies in Graves’ disease. Clin Chem Lab Med 55: 58-64.
Autilio C, Morelli R, Locantore P, et al. (2018): Stimulating TSH receptor autoantibodies immunoassay: analytical evaluation and clinical performance in Graves’ disease. Ann Clin Biochem 55: 172-177.
Frank CU, Braeth S, Dietrich JW, et al. (2015): Bridge Technology with TSH Receptor Chimera for Sensitive Direct Detection of TSH Receptor Antibodies Causing Graves’ Disease: Analytical and Clinical Evaluation. Horm Metab Res 47: 880-888.
Massart C, Sapin R, Gibassier J, at al. (2009): Intermethod variability in TSH- receptor antibody measurement: implications for the diagnosis of Graves’ disease and for the follow up of Graves’ ophthalmopathy. Clin Chem 55: 183-186.
Lytton SD, Ponto KA, Kanitz M, et al. (2010): A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves’ orbitopathy. J Clin Endocrinol Metab 95: 2123-2131.
Bartalena L, Veronesi G, Krassas GE, et al. (2017): Does early response to intravenous glucocorticoids predict the final outcome in patients with moderate-to-severe and active Graves’ orbitopathy? J Endocrinol Invest 40: 547-553.
Khoo TK, Bahn RS (2007): Pathogenesis of Graves’ Ophthalmopathy: The Role of Autoantibodies. Thyroid 17: 1013-1018.
Kumar S, Nadeem S, Stan MN, et al. (2011): A stimulatory TSH receptor antibody enhances adipogenesis via phosphoinositide 3-kinase activation in orbital preadipocytes from patients with Graves’ ophthalmopathy. J Mol Endocrinol 46: 155-163.
Jang SY, Shin DY, Lee EJ, et al. (2013): Relevance of TSH-receptor antibody levels in predicting disease course in Graves’ orbitopathy: comparison of the third-generation TBII assay and Mc4-TSI bioassay. Eye (Lond) 27: 964-971.
Ponto KA, Kanitz M, Olivo PD, et al. (2011): Clinical relevance of thyroid-stimulating immunoglobulins in Graves’ ophthalmopathy. Ophthalmology 118: 2279-2285.
Noh JY, Hamada N, Inoue Y, et al. (2000): Thyroid-stimulating antibody is related to Graves’ ophthalmopathy, but thyrotropin-binding inhibitor immunoglobulin is related to hyperthyroidism in patients with Graves’ disease. Thyroid 10: 809-813.
Khoo DH, Ho SC, Seah LL, et al. (1999): The combination of absent thyroid peroxidase antibodies and high thyroid-stimulating immunoglobulin levels in Graves’ disease identifies a group at markedly increased risk of ophthalmopathy. Thyroid 9: 1175-1180.
Stan MN, Bahn RS (2010): Risk Factors for Development or Deterioration of Graves’ Ophthalmopathy. Thyroid 20: 777-783.
Bitcon V, Donnelly J, Kiaei D (2016): Sensitivity of assays for TSH-receptor antibodies. J Endocrinol Invest 39: 1195-1196.
Diana T, Wuster C, Kanitz M, Kahaly GJ (2016): Highly variable sensitivity of five binding and two bio-assays for TSH-receptor antibodies. J Endocrinol Invest 39: 1159-1165.
Jonas M, Ambroziak U, Nauman J (2006): Correlation between thyroid stimulating immunoglobulins and thyrotropin binding inhibitory immunoglobulins levels in patients with Graves’ disease. Endokrynol Pol 57: 23-30.
Leo M, Mautone T, Ionni I, et al. (2016): Variables Affecting the Long-Term Outcome of Graves Orbitopathy Following High-Dose Intravenous Glucocorticoid Pulse Therapy in Patients Not Treated with Orbital Radiotherapy. Endocr Pract 22: 1177-1186.
Jagiello-Korzeniowska A, Sokolowski A, Krzentowska-Korek A, et al. (2016): The efficacy of immunosuppressive treatment of Graves’ orbitopathy is not affected by previous anti-thyroid drugs or by radioiodine therapy of Graves’ disease. Endokrynol Pol 67: 554-561.
Laurberg P, Wallin G, Tallstedt L, et al. (2008): TSH-receptor autoimmunity in Graves’ disease after therapy with anti-
thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. Eur J Endocrinol 158: 69-75.
FEATURED PRODUCTS
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe